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Abstract
Background:  Suppressor of cytokine signaling 3 (SOCS3) is considered to inhibit cytokine
responses and play a negative role in migration of various cells. Proline-rich tyrosine kinase 2
(PYK2) is a non-receptor kinase and has been found crucial to cell motility. However, little is known
about whether SOCS3 could regulate PYK2 pro-migratory function in lung cancer.
Methods: The methylation status of SOCS3 was investigated in HBE and A549 cell lines by
methylation-specific PCR. A549 cells were either treated with a demethylation agent 5-aza-2'-
deoxycytidine or transfected with three SOCS3 mutants with various functional domains deleted.
Besides, cells were pretreated with a proteasome inhibitor β-lactacystin where indicated. The
effects of SOCS3 up-regulation on PYK2 expression, PYK2 and ERK1/2 phosphorylations were
assessed by western blot using indicated antibodies. RT-PCR was used to estimate PYK2 mRNA
levels. Transwell experiments were performed to evaluate cell migration.
Results: SOCS3 expression was found impaired in A549 cells and higher PYK2 activity was
correlated with enhanced cell migration. We identified that SOCS3 was aberrantly methylated in
the exon 2, and 5-aza-2'-deoxycytidine restored SOCS3 expression. Reactivation of SOCS3
attenuated PYK2 expression and phosphorylation, cell migration was inhibited as well. Transfection
studies indicated that exogenous SOCS3 interacted with PYK2, and both the Src homology 2 (SH2)
and the kinase inhibitory region (KIR) domains of SOCS3 contributed to PYK2 binding.
Furthermore, SOCS3 was found to inhibit PYK2-associated ERK1/2 activity in A549 cells. SOCS3
possibly promoted degradation of PYK2 in a SOCS-box-dependent manner and interfered with
PYK2-related signaling events, such as cell migration.
Conclusion: These data indicate that SOCS3 negatively regulates cell motility and decreased
SOCS3 induced by methylation may confer a migration advantage to A549 cells. These results also
suggest a negative role of SOCS3 in PYK2 signaling, and a previously unidentified regulatory
mechanism for PYK2 function.
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Background
Proline-rich tyrosine kinase 2 (PYK2) is a ubiquitously
expressed non-receptor protein tyrosine kinase that con-
tributes to integrate signals from receptor tyrosine kinases
and intracellular signaling molecules in processes such as
cell survival [1], proliferation [2] and motility [3]. PYK2 is
hard to detect in early embryos [4], however macrophages
from PYK2-knockout embryos demonstrate severe migra-
tion and function defects [5], and loss of Pyk2 kinase
activity induces prostate cells to acquire a malignant,
migratory phenotype [6]. Conversely, enhanced PYK2 sig-
naling facilitates cell survival in an anchorage-independ-
ent manner [7], and promotes cell motility [8]. Moreover,
inhibition of Pyk2 mostly results in decreased cell migra-
tion [9,10]. Along these lines, report has been shown that
PYK2 expression and/or its activity are up-regulated in
invasive cancer cells [11]. Ligand binding of receptor tyro-
sine kinase results in autophosphorylation at Tyr402,
which serves as a binding site for several Src homology 2
(SH2) domain-containing proteins, such as Src kinase.
The PYK2-Src complex leads to further phosphorylation
of PYK2, resulting in activation of a number of cytoskele-
ton-linked proteins, which transduce signals to down-
stream pathways, such as the mitogen-activated protein
(MAP) kinase cascades, and leads to control of cell sur-
vival [12], proliferation [13], and migration [14]. At
present, little is known about the molecular mechanisms
that negatively regulate PYK2 function in lung cancer.
Suppressor of cytokine signaling 3 (SOCS3) is a member
of SOCS family and acts in a feedback loop to inhibit
cytokine responses and STAT3 activation in various cells
[15-17]. Evidence has indicated that SOCS3 regulates
other signaling pathways as well [18,19]. SOCS3 expres-
sion is suppressed due to aberrant methylation in its pro-
moter region, which frequently occurs in a variety of
human tumors [20,21]. The SOCS3 protein is structurally
composed of distinct functional domains, including a N-
terminal kinase inhibitory region, a central SH2 domain
and a C-terminal homologous region termed SOCS-box.
In many cases, SOCS3 interacts with phosphorylated tyro-
sine residues mediated by the SH2 and KIR domains, and
negatively regulates activities of tyrosine kinases [22,23].
The SOCS-box may act as a bridge to mediate degradation
of target proteins that interact with SOCS3-SH2 by the
proteasome pathway. Researches have proved that SOCS3
not only regulates the STAT3 signaling pathway [24] but
also the FAK tyrosine kinase [25].
We report here that SOCS3 was down-regulated due to
methylation in the exon 2 and reactivated after 5-aza-2'-
deoxycytidine treatment in A549 cells. SOCS3 was found
to interact with PYK2 by its SH2 and KIR domains, and
facilitate PYK2 degradation via proteasome pathway, and
to inhibit Tyr402 and ERK1/2 phosphorylations as well as
PYK2-associated migration of A549 cells. These results
identify a potential role of SOCS3 in regulating PYK2 sig-
naling.
Methods
Cells treatment and transfection
HBE cells (human bronchial epithelial) were grown in
RPMI 1640, and A549 cells (human lung adenocarci-
noma) were cultured in DMEM, both supplemented with
10% fetal bovine serum. The SOCS3-SH2, SOCS3-KIR
and SOCS-box mutants were kind gifts from Dr. Kristiina
Vuori (Burnham Institute, CA, USA). The SOCS3-SH2
mutant is a full length SOCS3 without the SH2 region,
consisting of the KIR and SOCS-box domains. The KIR
domain is knocked out in the SOCS3-KIR mutant, with
the SH2 and SOCS-box regions remained. And the SOCS-
box mutant contains the SH2 and KIR domains, with the
SOCS-box deleted. A myc tag was added to each of these
SOCS3 mutants, and exogenous SOCS3 mutants were
represented by the detection of myc tag. The schematic
representations of the three SOCS3 mutants with distinct
functional domains deleted were shown in Fig. 1. For the
reactivation study, A549 cells (50–60% confluence) were
treated with 10 μM 5-aza-2'-deoxycytidine (Sigma) for 6
days, and medium was changed every other day. DNA and
RNA as well as protein were extracted and analyzed as
described below. To exogenously express SOCS3 for sub-
sequent analysis, A549 cells (80–90% confluence) were
transfected with either SOCS3 mutants or pcDNA3 vector
for 48 h using Lipofectamin2000 (Invitrogen), according
to the manufacturer's instructions. Where indicated, the
proteasome inhibitor, β-lactacystin (Santa Cruz) at 25 μM
was added to cells and maintained throughout the exper-
iments.
Methylation-specific PCR
Methylation-specific PCR (MSP) was carried out as
described previously [26]. The methylation-specific and
unmethylation-specific primers were designed using the
Methyl Primer Express software v1.0 (ABI). Sequences of
methylation-specific primers in the exon 2 of SOCS3 were
5'-TTC GAG GTG TTC GAG TAG TC-3' (forward) and 5'-
AAC GAT CTT CCG ACA AAA AT-3' (reverse); sequences
of unmethylation-specific primers were 5'-TTT TTT GAG
GTG TTT GAG TAG TT-3' (forward) and 5'-AAC AAT CTT
CCA ACA AAA ATA CT-3' (reverse), and the lengths of
PCR products were both 159 bp. PCR was carried out by
an initial denaturation step at 95°C for 10 min, followed
by 40 cycles of denaturation at 95°C for 40 s, annealing at
63°C (methylation) or 62°C (unmethylation) for 40 s,
and elongation at 72°C for 40 s. Cycling was completed
by a final elongation step at 72°C for 10 min. Sequences
of the other two MSP primer sets for exon 1 and intron 1
of SOCS3 are available upon request.BMC Cancer 2008, 8:150 http://www.biomedcentral.com/1471-2407/8/150
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RT-PCR analysis
Total RNA was prepared using Trizol (Invitrogen). cDNA
was generated by reverse transcription of 1 μg total RNA
using Reverse Transcriptase M-MLV (Takara). The primer
sequences of PYK2 were 5'-AGA TTC CCG ACG AAA CCC-
3' (forward) and 5'-CAC GGC GAA CAT CCA GAC-3'
(reverse), and that of β-actin were 5'-AAA TCG TGC GTG
ACA TTA A-3' (forward) and 5'-CTCGTCATACTCCT-
GCTTG-3' (reverse). The lengths of PYK2 and β-actin PCR
products were 629 bp and 455 bp respectively. PCR was
carried out by an initial denaturation step at 94°C for 5
min, followed by 35 cycles of denaturation at 94°C for 40
s, annealing at 54°C for 40 s, and elongation at 72°C for
40 s. Cycling was completed by a final elongation step at
72°C for 5 min. The PCR for β-actin was performed in the
same manner as PYK2, except that 30 cycles of annealing
at 50°C was used. The EC3 Imaging system (UVP Inc.)
was used to catch up the specific bands, and the optical
density of each band was measured using the Image J soft-
ware.
Western blot and co-immunoprecipitation analysis
Cells were washed twice with ice-cold phosphate buffered
saline (PBS) and lysed in M-PER reagent (PIERCE) con-
taining 1 mM PMSF and phosphatase inhibitors. The fol-
lowing primary antibodies were used in this study: mouse
monoclonal anti-myc tag (Applygen, China), rabbit poly-
clonal anti-SOCS3, anti-PYK2, anti-p-Tyr40, anti-β-actin,
and mouse monoclonal anti-p-ERK1/2 antibodies (all
from Santa Cruz). Cells were lysed at 6 d after 5-aza-2'-
deoxycytidine treatment or 48 h post-transfection, and the
lysates were subjected to SDS-PAGE followed by western
blot analysis. Where indicated, cells were pretreated with
β-lactacystin 4 h before 5-aza-2'-deoxycytidine treatment
or transfection and maintained throughout the experi-
ments. The co-immunoprecipitation study was performed
using the profound mammalian c-myc tag IP/Co-IP kit
(PIERCE), according to the manufacturer's protocols.
Clarified cell extracts were preincubated with agarose cou-
pled with anti-myc tag antibody at 4°C overnight fol-
lowed by SDS-PAGE and detected with anti-PYK2
antibody. The EC3 Imaging system (UVP Inc.) was used to
catch up the specific bands, and the optical density of each
band was measured using the Image J software.
Transwell cell migration assay
Cell migration assay was performed using a 24-well Tran-
swell chamber (Costar). At 6 d following 5-aza-2'-deoxy-
cytidine treatment, cells (1 × 104) were detached and
seeded in the upper chamber of a 8 μm pore size insert in
the 24-well plate and cultured for another 12 h. At 48 h
after transfection, cells were treated similarly as described
above. Cells were allowed to migrate forward to DMEM
containing 15% FBS in the bottom chamber. The non-
migratory cells on the upper membrane surface were
removed with a cotton tip, and the migratory cells
attached to the lower membrane surface were fixed with
4% paraformaldehyde and stained with hematoxylin. The
Schematic representations of SOCS3 and three mutants with distinct functional domains deleted Figure 1
Schematic representations of SOCS3 and three mutants with distinct functional domains deleted. The SOCS3 
protein is structurally characterized by three distinct functional domains that include a N-terminal kinase inhibitory region 
(white), a central SH2 domain (black) and a C-terminal homologous region SOCS-box (gray). (a) The SOCS3-SH2 mutant is a 
full length SOCS3 without the SH2 region, consisting of the KIR and SOCS-box domains. (b) The KIR region is knocked out in 
the SOCS3-KIR mutant, with the SH2 and SOCS-box domains remained. (c) The SOCS-box mutant contains the SH2 and KIR 
domains, with the SOCS-box deleted. A myc tag was added to each of these SOCS3 mutants, and exogenous SOCS3 mutants 
were represented by the detection of myc tag.BMC Cancer 2008, 8:150 http://www.biomedcentral.com/1471-2407/8/150
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number of migrated cells was counted in five randomly
selected high power fields under microscope. Data pre-
sented are representative of three individual wells.
Statistical analysis
The SPSS 13.0 software was applied to complete data
processing. Independent-samples t-test was used to evalu-
ate the differences of optical density (OD) values or num-
bers of migrated cells between groups with various
treatments. All data were represented as mean ± SD of
three independent experiments. Results were considered
statistically significant when the p-value was less than
0.05 [see Additional file 1].
Results
Up-regulation of PYK2 expression, Tyr402 and ERK1/2 
phosphorylations, as well as cell migration in A549 cells
PYK2 expression and activation, as indicated by Tyr402
phosphorylation, and ERK1/2 phosphorylation were eval-
uated in HBE and A549 cells respectively. As normal lung
cells, HBE cells expressed a low level of PYK2 with an
undetectable phosphorylated Tyr402. A basal ERK1/2
phosphorylation was also observed in HBE cells. How-
ever, we found much higher expression of PYK2 as well as
Tyr402 and ERK1/2 phosphorylations in A549 cells (p <
0.05, Fig. 2a). Additionally, more migrated A549 cells
(16.9 ± 3.6) at 12 h were detected than HBE cells (7.9 ±
1.9, p < 0.05, Fig. 2b) by Transwell assay.
Methylation-associated down-regulation of SOCS3 in 
A549 cells
The expression of SOCS3 was examined in HBE and A549
cells. We found that SOCS3 expression was much lower in
A549 than HBE cells (p < 0.05, Fig. 3a). Researches on
human cancers have indicated that down-regulation of
SOCS3 was correlated with aberrant methylation. Thus, in
our studies, three methylation- and non-methylation-spe-
cific primer sets were used to detect methylation status of
SOCS3 in the exon 1, intron 1 and exon 2 in A549 cells
respectively. As shown in Fig. 3a, methylation of SOCS3
in the exon 2, which lies in a region of 92–250 bp down-
stream to the translation start site, was detected in A549
cells, although no detectable methylation was found in
the noncoding exon 1 and intron 1 (data not shown).
Moreover, no methylation was observed in HBE cells as
well. Therefore, methylation in the exon 2 was correlated
with the decrease of SOCS3 expression in A549 cells. The
non-methylation specific amplification instead of methyl-
ation was detected after the demethylation agent 5-aza-2'-
deoxycytidine treatment, and SOCS3 expression was
restored (p < 0.05, Fig. 3b), which further demonstrated
that SOCS3 was methylated in A549 cells.
Up-regulation of SOCS3 inhibited cell migration and 
associated PYK2 expression, Tyr402 and ERK1/2 
phosphorylations in A549 cells
To investigate whether SOCS3 involves in regulating cell
migration, the number of migrated A549 cells with 5-aza-
PYK2 expression, Tyr402 and ERK1/2 phosphorylations, as well as cell migration in HBE and A549 cells Figure 2
PYK2 expression, Tyr402 and ERK1/2 phosphorylations, as well as cell migration in HBE and A549 cells. (a) 
PYK2 expression, Tyr402 and ERK1/2 phosphorylations in HBE and A549 cells by western blot. (b) Comparisons of migratory 
abilities between HBE and A549 cells by Transwell assay. The data are representative of three individual experiments.BMC Cancer 2008, 8:150 http://www.biomedcentral.com/1471-2407/8/150
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2'-deoxycytidine treatment or not was evaluated. The
numbers of migrated cells with or without 5-aza-2'-deox-
ycytidine treated and with β-lactacystin pretreatment were
9.2 ± 3.4, 16.9 ± 3.6 and 13.4 ± 3.3, respectively (p < 0.05,
Fig. 4c). We also identified that PYK2 expression, Tyr402
and ERK1/2 phosphorylations were suppressed upon
SOCS3 up-regulation by 5-aza-2'-deoxycytidine treatment
(p < 0.05, Fig. 4a) and the decreased Tyr402 phosphoryla-
tion was in parallel with the reduced PYK2 expression
which was possibly attributed to the process of proteolytic
degradation, because elevated PYK2 expression was
detected in cells pretreated with the proteasome inhibitor
β-lactacystin (p < 0.05, Fig. 4a), and PYK2 mRNA levels
were unaffected (p > 0.05, Fig. 4b).
Roles of SOCS3 mutants in regulating PYK2 expression, 
Tyr402 and ERK1/2 activations and migration of A549 cells
Concurred with PYK2 expression, cells with the SH2
domain deleted SOCS3 showed phosphorylations of
Tyr402 and ERK1/2 were identical to that in the vector
alone-transfected cells (p > 0.05, data not shown). The
numbers of migrated cells transfected with vector and
SOCS3-SH2 mutant were 16.1 ± 3.8, 15.7 ± 3.5, respec-
tively (p > 0.05, data not shown).
Cells with the KIR domain inactivated SOCS3 showed
reduced PYK2 expression, as well as PYK2 and ERK1/2
phosphorylations (p < 0.05, Fig. 5a), which were in paral-
lel with inhibited cell migration. The numbers of migrated
cells with vector or SOCS3-KIR mutant transfection, and
β-lactacystin pretreatment were 16.1 ± 3.8, 10.3 ± 2.9 and
13.8 ± 3.6, respectively (p < 0.05, Fig. 5c). To further deter-
mine whether the suppressed cell migration was induced
by SOCS-box-mediated proteasome-dependent degrada-
tion of PYK2, pretreatment with β-lactacystin was per-
formed in transfected cells, and PYK2 mRNA levels were
also examined. We found that β-lactacystin elevated PYK2
expression, and the number of migrated cells also
increased. However, PYK2 mRNA levels were unchanged
(p > 0.05, Fig. 5b). These results indicated that the inhib-
ited migration of A549 cells was possibly correlated with
proteasome-mediated degradation of PYK2.
Methylation status and expression of SOCS3 in HBE and A549 cells Figure 3
Methylation status and expression of SOCS3 in HBE and A549 cells. (a) Methylation status of SOCS3 in HBE and 
A549 cells, using the primer set designed in the exon 2, and detection of SOCS3 expression by western blot. The observed 
bands in lane M are methylated 159 bp products with methylation-specific primers and that in lane U are unmethylated 159 bp 
products with unmethylation-specific primers. Methylation was found in A549 cells but not in HBE cells and HBE cells 
expressed higher level of SOCS3. (b) The visible band in lane U appeared in A549 cells and SOCS3 was reactivated by the 
treatment of 5-aza-2'-deoxycytidine. The results are representative of three independent experiments.BMC Cancer 2008, 8:150 http://www.biomedcentral.com/1471-2407/8/150
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Up-regulation of SOCS3 by 5-aza-2'-deoxycytidine treatment inhibited cell migration and associated PYK2 expression, Tyr402  and ERK1/2 phosphorylation Figure 4
Up-regulation of SOCS3 by 5-aza-2'-deoxycytidine treatment inhibited cell migration and associated PYK2 
expression, Tyr402 and ERK1/2 phosphorylations. (a) Decreased PYK2 expression, Tyr402 and ERK1/2 activations and 
migration of A549 cells were observed by SOCS3 up-regulation. A549 cells were treated with 5-aza-2'-deoxycytidine for 6 d, 
and cell lysates were analysed by western blot using the indicated antibodies. Elevated PYK2 expression, Tyr402 and ERK1/2 
phosphorylations were found by the pretreatment of β-lactacystin. (b) PYK2 mRNA levels remained invariable regardless of 
treatment or not. The amplified PYK2 products were 629 bp in length. β-actin amplification demonstrated the consistency of 
PT-PCR. (c) Cell migration was suppressed by SOCS3 restoration, and the β-lactacystin pretreatment facilitated cell migration 
to some extent. The values are means of three replicates.
Effects of SOCS3-KIR mutant on PYK2 expression, Tyr402 and ERK1/2 activations and migration of A549 cells Figure 5
Effects of SOCS3-KIR mutant on PYK2 expression, Tyr402 and ERK1/2 activations and migration of A549 cells. 
(a) Down-regulations of PYK2 expression, Tyr402 and ERK1/2 phosphorylations by SOCS3-KIR mutant. A549 cells were 
transfected with either vector or the SOCS3-KIR mutant for 48 h, and cell lysates were subjected to western blot using the 
indicated antibodies. Cells pretreated with β-lactacystin showed that PYK2 expression, Tyr402 and ERK1/2 phosphorylations 
were restored to some extent. (b) PYK2 mRNA levels were unaffected regardless of transfection or not. The amplified PYK2 
products were 629 bp in length. β-actin amplification demonstrated the consistency of PT-PCR. (c) Cell migration inhibited by 
the SOCS3-KIR mutant was statistically significant, and β-lactacystin pretreatment restored cell migration to some degree. The 
values are means of three replicates.BMC Cancer 2008, 8:150 http://www.biomedcentral.com/1471-2407/8/150
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Next, A549 cells were transfected with SOCS-box mutant.
Compared with the vector alone-transfected cells, Tyr402
and ERK1/2 phosphorylations were inhibited (p < 0.05,
Fig. 6a), despite that these cells expressed similar level of
PYK2 as control cells (p > 0.05, Fig. 6a). Pretreatment with
β-lactacystin was also performed in transfected cells and
no effects were detected on PYK2 expression, Tyr402 and
ERK1/2 activations (p > 0.05, Fig. 6a). PYK2 mRNA levels
were unchanged as well (p > 0.05, Fig. 6b). The numbers
of migrated cells with vector or SOCS-box mutant trans-
fection, and β-lactacystin pretreatment were 16.1 ± 3.8,
13.8 ± 4.5 and 14.2 ± 4.2, respectively (p > 0.05, Fig. 6c).
The SOCS-box inactivated mutant failed to decrease PYK2
expression and inhibit cell migration. The suppressed
phosphorylations of Tyr402 and ERK1/2 were possibly
due to the kinase inhibitory activity of SOCS3.
Interactions of exogenous SOCS3 mutants with PYK2 in 
A549 cells
We further investigated whether exogenously expressed
SOCS3 mutants interacted with PYK2 in the transfected
A549 cells. As shown in Fig. 7, exogenous SOCS3-SH2, -
KIR and -box mutants were detected in A549 cells, as indi-
cated by the myc tag. PYK2 was co-immunoprecipitated
with exogenous myc tag, which is clearly seen in SOCS-
box mutant-transfected A549 cells but not in vector con-
trol cells. However, neither SOCS3-SH2 nor -KIR mutant/
PYK2 co-IP product was observed in transfected A549 cells
(Fig. 7). These results collectively suggested that the SH2
and KIR domains were essential for SOCS3 interacting
with PYK2, and the formation of SOCS3/PYK2 complex
may result in inhibited migration of A549 cells.
Discussion
Although much progress has been made on elucidating
the PYK2 downstream signaling pathways, relatively little
is known about the regulatory mechanisms of PYK2. Our
studies in this report demonstrated that SOCS3 might
have a previously unidentified role in negatively regulat-
ing PYK2 function. The expression of SOCS3 is decreased
due to aberrant methylation, and its transcriptional
silencing is associated with malignant tumor behaviors
[27]. Human SOCS3 gene is composed of the noncoding
exon 1, intron 1 and exon 2. In our studies, the methyla-
tion- and non-methylation-specific primers were used to
detect methylation status of SOCS3 in the exon 1, intron
1 and exon 2 in A549 cells respectively. We found SOCS3
methylation in the exon 2, which lies in a region of 92–
250 bp downstream to the translation start site, although
no detectable methylation was found in the promotor
region containing the noncoding exon 1 and intron 1,
which was consistent with the previous findings [28]. This
demonstrated that methylation in the exon 2 was associ-
ated with the decrease of SOCS3 expression in A549 cells.
The demethylation agent 5-aza-2'-deoxycytidine reacti-
vated SOCS3, which further indicated that SOCS3 expres-
sion was attenuated by the associated methylation. Taken
together, the exon 2 of SOCS3 appeared to be a crucial tar-
get for methylation in A549 cells. However, the signifi-
cance of methylation in exons has not been elucidated.
Effects of SOCS-box mutant on PYK2 expression, Tyr402 and ERK1/2 activations and cell migration Figure 6
Effects of SOCS-box mutant on PYK2 expression, Tyr402 and ERK1/2 activations and cell migration. (a) 
Decreased PYK2 and ERK1/2 phosphorylations by SOCS-box mutant with the same PYK2 expression. A549 cells were vector- 
or the SOCS-box mutant-transfected for 48 h, and cell lysates were analysed by western blot using the indicated antibodies. (b) 
PYK2 mRNA levels were unaffected regardless of transfection or not. The amplified PYK2 products were 629 bp in length. β-
actin amplification demonstrated the consistency of PT-PCR. (c) Cell migration suppressed by the SOCS-box mutant was not 
statistically significant. The values are means of three replicates.BMC Cancer 2008, 8:150 http://www.biomedcentral.com/1471-2407/8/150
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It has been shown that SOCS3 transfection inhibited pro-
liferation of A549 cells [15]. We therefore examined the
effect of SOCS3 up-regulation on migration of A549 cells.
In our studies, we found that SOCS3 restoration inhibited
cell migration. The negative regulation of SOCS3 was pre-
viously reported in PDGF-induced fibroblast [29] and
HGF-promoted keratinocyte migration [30], which was
mediated by STAT3. However, STAT3 pathway may not be
involved in SOCS3 methylation-induced migration of
A549 cells, because STAT3 binding sites [25] are not
included in the exon 2 of SOCS3. These data supported
that SOCS3 methylation-associated inactivation might
facilitate cell motility, and SOCS3 reactivation by 5-aza-
2'-deoxycytidine treatment inhibited migration of A549
cells.
A growing number of reports have demonstrated that
PYK2 plays a significant role in development of various
tumors. In metastatic glioma cells and hepatocellular car-
cinoma, PYK2 expression is significantly elevated [31,32].
PYK2 becomes Tyr402-phosphorylated in invasive breast
cancer [33] and SCLC cells [34], and PYK2-associated
ERK1/2 activation participates in up-regulating the adhe-
sive ability of PCa cells [35]. Pyk2 becomes activated by a
number of cytokines that are also known to regulate
SOCS3, such as SDF-1/CXCL12 [2,18]. As a negative regu-
lator for PYK2 in T cells, SOCS3 showed migration sup-
pression activity [36]. We also notice that SOCS3 binds to
the phosphorylated Tyr397 of FAK, a close homolog of
PYK2, and inhibits its kinase activity or induces degrada-
tion by proteasome pathway [19]. Thus, similar mecha-
nisms of interaction and inhibition could apply to PYK2.
We found that PYK2 expression, Tyr402 and ERK1/2
phosphorylations were inhibited with the increasing
expression of SOCS3 by the treatment of 5-aza-2'-deoxy-
cytidine. PYK2 seemed to be down-regulated by proteas-
ome-mediated degradation, because pretreatment with β-
lactacystin restored PYK2 expression, Tyr402 and ERK1/2
phosphorylations to some extent and PYK2 mRNA levels
were unchanged no matter whether treatment or not. As
we concluded, inhibited migration of A549 cells was asso-
ciated with the reduced PYK2 expression, Tyr402 and
ERK1/2 phosphorylations after SOCS3 restoration.
We further examined the effects of SOCS3 mutants on cell
motility, and the associated PYK2 expression, Tyr402 and
ERK1/2 phosphorylations. When SOCS3-SH2 mutant
exogenously expressed in A549 cells, the PYK2 expression,
Tyr402 and ERK1/2 phosphorylations, as well as cell
migration were unchanged regardless of whether transfec-
tion or not. Moreover, the interaction of exogenous
SOCS3-SH2 mutant with PYK2 was not detected. These
findings indicated that the SH2 region inactivated mutant
deprived SOCS3 of the ability to down-regulate PYK2-
associated signaling and function in A549 cells. Therefore,
the SH2 domain is crucial for SOCS3 regulating PYK2.
Compared with control cells, A549 cells with SOCS3-KIR
mutant showed decreased PYK2 expression. Tyr402 and
ERK1/2 phosphorylations, as well as cell mobility. Pre-
treatment with β-lactacystin restored PYK2 expression,
Tyr402 and ERK1/2 phosphorylations, and cell migration
to some extent. We proposed that the binding of SOCS3
with PYK2 via SH2 domain and SOCS-box-mediated pro-
teasome-dependent degradation of PYK2 led to the sup-
pressed migration of transfected A549 cells. The roles of
SOCS3-KIR mutant were observed definitely, however the
potential interaction as we presumed between the exoge-
nous SOCS3-KIR mutant and PYK2 was not detected. We
supposed that SOCS3-KIR mutant interacted with PYK2
principally by the central SH2 domain, generating the
inhibition effects, however the binding was a functional
interaction, unstable and readily reversible, and the effects
would be transient without the help of KIR domain, thus
could not be detected by immunoprecipitation in vitro.
Therefore we concluded that the KIR domain is possibly
required for a more stable binding of SOCS3 with PYK2
Interactions of exogenously expressed SOCS3 mutants with  PYK2 in A549 cells Figure 7
Interactions of exogenously expressed SOCS3 
mutants with PYK2 in A549 cells. A549 cells were trans-
fected with either vector or SOCS3 mutants with distinct 
functional domains deleted, and pretreated with β-lactacystin 
4 h before transfection until the cell lysates were subjected 
to anti-myc tag immunoprecipitations and analysed by west-
ern blot using the anti-PYK2 antibody. The co-immunopre-
cipitation product was clearly observed in the SOCS-box 
mutant transfected cells. The results are representative of 
three individual experiments.BMC Cancer 2008, 8:150 http://www.biomedcentral.com/1471-2407/8/150
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based on the SH2 domain. Further investigation is
required to demonstrate our point of view.
The SOCS-box mutant had no influence on PYK2 expres-
sion, but Tyr402 and ERK1/2 phosphorylations were
reduced in contrast to control cells. The migration of
transfected A549 cells was also inhibited. These data
denoted that the SOCS-box inactivated mutant down-reg-
ulated PYK2-associated signaling and function possibly
by binding to PYK2 via the SH2 domain and inhibiting
PYK2 activation by the KIR domain. PYK2 was detected in
cell lysates immunoprecipitated with anti-myc tag anti-
body, which suggested a direct interaction between SOCS-
box mutant and PYK2. Taken together, the stable interac-
tion between exogenous SOCS3 and PYK2 is dependent
on the SH2 and KIR domains of SOCS3, which results in
the observed decrease in PYK2 expression, leading to the
subsequent Tyr402 and ERK1/2 inactivations.
Studies have demonstrated that Tyr402 phosphorylation
of PYK2 leads to binding of the SH2 domain and activa-
tion of Src [37], or integration of the SH2 domain of CHK
and inhibition of breast cancer cell migration [38]. Our
results are suggestive of an important role of SOCS3 in
blocking Tyr402 phosphorylation. However, it remains to
be determined whether Tyr402 mediates the interaction
between SOCS3 and PYK2. Moreover, the precise role of
SOCS3 in regulating migration-associated cytoskeleton
proteins downstream of PYK2 has not been characterized
in relation to lung cancer metastasis. Taken together, our
results indicate that SOCS3 interacts with PYK2 and
inhibits PYK2-associated migration of A549 cells. Further
research is needed to clarify the pathological significance
of PYK2 expression and interaction with SOCS3 in various
signaling pathways. Studies of SOCS3 may foster new
anti-chemotactic approaches to suppress lung cancer
metastasis.
Conclusion
Our data suggested that SOCS3 negatively regulates cell
motility and decreased SOCS3 induced by methylation
may confer a migration advantage to A549 cells. Exoge-
nous SOCS3 interacted with PYK2, and both the SH2 and
KIR domains of SOCS3 contributed to PYK2 binding.
These results also suggest a negative role of SOCS3 in
PYK2 signaling, and a previously unidentified regulatory
mechanism for PYK2 function.
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